Molecular Endocrinology, Vol 5, 1887-1896, Copyright © 1991 by Endocrine Society

ARTICLES

Differential binding of transforming growth factor-beta 1, -beta 2, and -beta 3 by fibroblasts and epithelial cells measured by affinity cross- linking of cell surface receptors

RM Lyons, DA Miller, JL Graycar, HL Moses and R Derynck
Department of Cell Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.

A murine fibroblast cell line (AKR-2B clone 84A) and an epithelial cell line (BALB/MK) were compared for their ability to bind different transforming growth factor-beta (TGF beta) species. The results of competitive binding assays indicated that the epithelial cells had a higher affinity for TGF beta than the fibroblasts. This difference may be the basis for the sensitivity of epithelial cells to much lower concentrations of TGF beta than fibroblasts. Affinity cross-linking studies showed that both cell types express the three cell surface TGF beta-binding molecules that have been previously described for a variety of cell types. The complexity of these cell surface binding proteins was further evaluated using all possible combinations of radiolabeled ligands in competition with each of the three unlabeled TGF beta species. Differences in the ability of specific TGF beta types to compete with radiolabeled TGF beta 2 for binding to the type I and II receptors were observed, with TGF beta 1 being more potent for epithelial cells, and TGF beta 2 being more potent for fibroblasts. In addition, a difference in the ability of different TGF beta species to compete the [125I]TGF beta 3 from epithelial cell surface receptors was apparent. TGF beta 2 was not able to compete with [125I]TGF beta 3 for binding to the type II receptor at any concentration tested, while TGF beta 1 and TGF beta 3 were about equally potent in competition for this receptor type. These differences in cell surface receptor binding of structurally and biologically similar molecules may reflect different functions for these molecules.

This article has been cited by other articles:

				E. V. Verona, Y. Tang, T. K. Millstead, A. P. Hinck, J. K. Agyin, and L.-Z. Sun Expression, purification and characterization of BGERII: a novel pan-TGF{beta} inhibitor Protein Eng. Des. Sel., July 1, 2008; 21(7): 463 - 473. [Abstract] [Full Text] [PDF]

				K. Suzuki, M. C. Wilkes, N. Garamszegi, M. Edens, and E. B. Leof Transforming Growth Factor {beta} Signaling via Ras in Mesenchymal Cells Requires p21-Activated Kinase 2 for Extracellular Signal-Regulated Kinase-Dependent Transcriptional Responses Cancer Res., April 15, 2007; 67(8): 3673 - 3682. [Abstract] [Full Text] [PDF]

				S. Hentges, M. Pastorcic, A. De, N. Boyadjieva, and D. K. Sarkar Opposing Actions of Two Transforming Growth Factor-{beta} Isoforms on Pituitary Lactotropic Cell Proliferation Endocrinology, April 1, 2000; 141(4): 1528 - 1535. [Abstract] [Full Text] [PDF]

				K. M. Koli, T. T. Ramsey, Y. Ko, T. C. Dugger, M. G. Brattain, and C. L. Arteaga Blockade of Transforming Growth Factor-beta Signaling Does Not Abrogate Antiestrogen-induced Growth Inhibition of Human Breast Carcinoma Cells J. Biol. Chem., March 28, 1997; 272(13): 8296 - 8302. [Abstract] [Full Text] [PDF]

				S Lawler, A. Candia, R Ebner, L Shum, A. Lopez, H. Moses, C. Wright, and R Derynck The murine type II TGF-beta receptor has a coincident embryonic expression and binding preference for TGF-beta 1 Development, January 1, 1994; 120(1): 165 - 175. [Abstract] [PDF]